XNCR News and Press, Xencor Inc. From 04/28/21

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that the first subject has been dosed in a randomized, double-blind, placebo-controlled ...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will release first quarter 2021 financial results after the market closes on Wed...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the presentation of new data from multiple preclinical XmAb ® bispecific antibod...

Lead product candidate, ZB001, has first-in-class potential in China for Thyroid Eye Disease Rapidly advancing seven pipeline programs, including three worldwide, with best-in-class potential in autoimmune and rare diseases Expanding a proven leadership...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will present preclinical data on three XmAb ® bispecific antibody programs a...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will participate in a ...

— Collaboration joins together Xencor's modular XmAb engineered protein platforms with UCLA's expertise in biology to rapidly create and advance potential new medicines — Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engi...

Xencor Inc (XNCR) Q4 2020 Earnings Conference Call February 23, 2021 4:30 PM ET Company Participants Charles Liles - Head of Investor Relations Bassil Dahiyat - President and Chief Executive Officer Allen Yang - Chief Medical Officer John Kuch - Chief Financial Officer John Desjarlais - Chief...

Image source: The Motley Fool. Xencor Inc (NASDAQ: XNCR) Q4 2020 Earnings Call Feb 23, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Xencor Inc (XNCR) Q4 2020 Earnings Call Transcript

Xencor (XNCR): Q4 GAAP EPS of -$0.24 beats by $0.12.Revenue of $41.85M (+1088.9% Y/Y) beats by $11.2M.Xencor expects to have cash to fund R&D programs and operations into 2024. Xencor expects to end 2021 with between $425-$475M in cash, cash equivalents and marketable securities.Shares +0...